N-terminal pro-Brain Natriuretic Peptide as a Predictor of Reoperation in Children With Surgically Corrected Tetralogy of Fallot

Hirono, Keiichi; Sekine, Michikazu; Shiba, Noriko; Hayashi, Shirou; Nakaoka, Hideyuki; Ibuki, Keijiro; Saito, Kazuyoshi; Watanabe, Kazuhiro; Ozawa, Sayaka; Higuma, Tomonori; Yoshimura, Naoki; Kitajima, Isao; Ichida, Fukiko

doi:10.1253/circj.cj-13-1048

Cited by 16 publications

(14 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[157][158][159]163,165 BNP in tetralogy of Fallot The clinical relevance of BNP in the integrated followup of patients after tetralogy of Fallot repair has been assessed in several studies. [167][168][169][170][171][172][173][174][175][176][177][178][179][180][181][182][183][184][185][186] Patients after tetralogy of Fallot correction can demonstrate a series of typical pathological sequelae, such as residual pulmonary regurgitation and/or stenosis, causing right ventricular dilatation, hypertrophy, or both. Patients with these cardiac alterations may be initially asymptomatic, but subsequently deteriorate progressively into having symptomatic heart failure.…”

Section: Bnp In the Follow-up Of Corrected/palliated Chdmentioning

confidence: 99%

“…167,168 At present, there are no solid guidelines for the management of these patients, in particular concerning the critical values of elevated right ventricular dimensions to take into account for an eventual re-intervention. [167][168][169][170][171][172][173][174][175][176][177][178][179][180][181][182][183][184][185][186] The use of BNP may provide important additional information both for the evaluation of asymptomatic individuals as well to grade and monitor the degree of heart failure. [8][9][10] In the last decade, a large number of studies have reported significant relationships between circulating levels of biomarkers and several structural and functional parameters as assessed by echocardiography and MRI.…”

Section: Bnp In the Follow-up Of Corrected/palliated Chdmentioning

confidence: 99%

“…[8][9][10] In the last decade, a large number of studies have reported significant relationships between circulating levels of biomarkers and several structural and functional parameters as assessed by echocardiography and MRI. [167][168][169][170][171][172][173][174][175][176][177][178][179][180][181][182][183][184][185] The majority of these studies have demonstrated a significant association between BNP levels and the degree of pulmonary regurgitation, right ventricular end-diastolic volume, and systolic pressure. [171][172][173][177][178][179]181 On the other hand, conflicting results were reported concerning the association between BNP levels with right ventricular function.…”

Section: Bnp In the Follow-up Of Corrected/palliated Chdmentioning

confidence: 99%

See 2 more Smart Citations

BNP in children with congenital cardiac disease: is there now sufficient evidence for its routine use?

et al. 2015

View full text Add to dashboard Cite

Interest in brain natriuretic peptide (BNP) and N-terminal pro-brain natriuretic peptide (NT-proBNP) in the management of children with CHD has increased. There are, however, no current guidelines for their routine use. The aim of this review article is to provide an update on the data regarding the use of BNP/NT-proBNP in the evaluation and surgical treatment of children with CHD. BNP/NT-proBNP levels in children with CHD vary substantially according to age, laboratory assay methods, and the specific haemodynamics associated with the individual congenital heart lesion. The accuracy of BNP/NT-proBNP as supplemental markers in the integrated screening, diagnosis, management, and follow-up of CHD has been established. In particular, the use of BNP/NT-proBNP as a prognostic indicator in paediatric cardiac surgery has been widely demonstrated, as well as its role in the subsequent follow-up of surgical patients. Most of the data, however, are derived from single-centre retrospective studies using multivariable analysis; prospective, randomised clinical trials designed to evaluate the clinical utility and cost-effectiveness of routine BNP/NT-proBNP use in CHD are lacking. The results of well-designed, prospective clinical trials should assist in formulating guidelines and expert consensus recommendations for its use in patients with CHD. Finally, the use of new point-of-care testing methods that use less invasive sampling techniques -capillary blood specimens -may contribute to a more widespread use of the BNP assay, especially in neonates and infants, as well as contribute to the development of screening programmes for CHD using this biomarker.

show abstract

Section: Bnp In the Follow-up Of Corrected/palliated Chdmentioning

confidence: 99%

Section: Bnp In the Follow-up Of Corrected/palliated Chdmentioning

confidence: 99%

Section: Bnp In the Follow-up Of Corrected/palliated Chdmentioning

confidence: 99%

See 1 more Smart Citation

BNP in children with congenital cardiac disease: is there now sufficient evidence for its routine use?

et al. 2015

View full text Add to dashboard Cite

show abstract

“…[41][42][43] Moreover, right ventricular volume overload due to pulmonary regurgitation after surgery for TOF also leads to increased NT-proBNP levels. [44,45] NT-proBNP levels have been reported as a useful marker of HF in patients with single ventricular circulation after Fontan surgery. [46][47][48] Accordingly, in the treatment of CHD, measurement of BNP and NT-proBNP levels is a useful tool to evaluate HF, to determine the effectiveness of therapeutic agents, and to identify the need for surgical intervention.…”

Section: Review Articlementioning

confidence: 99%

Cardiac biomarkers in children with congenital heart disease

et al. 2015

View full text Add to dashboard Cite

show abstract

“…In this paper, we applied the micro-ELISA system to detect a heart failure marker, brain natriuretic peptide (BNP), 11,12,13,14,15,16,17,18,19,20 which is one of the most difficult marker to detect and handle in clinics and home, because of the low concentration (pg/mL) and due to its instability (biological half-life: ~20 minutes). The sensitivity was enhanced by developing new analytical procedure (one step pre-mixed method).…”

Section: Introductionmentioning

confidence: 99%